City of Hope

City of Hope, a NCI-designated Comprehensive Cancer Center

Page Title

Skip Navigation

Global Navigation



Border Border
  
  PROFILE 
The following is a list of available studies directed by  Thehang Luu, MD  
Search results:  2  Clinical trial(s) found  (Page 1 of 1 )
Results per page: 25 50 100 All 1-2 Trials Jump to page:

COH Protocol Number: 13354 ClinicalTrials.gov Number: NCT01942135

Principal Investigator: Thehang Luu, MD
Sponsor: Industrial

Title:  Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Fulvestrant (Faslodex®) With or Without (PD-0332991 (Palbociclib) ± Goserelin in Women with Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer Whose Disease Progressed After Prior Endocrine Therapy

COH Protocol Number: 12077 ClinicalTrials.gov Number: NCT01528345

Principal Investigator: Thehang Luu, MD
Sponsor: Industrial

Title:  A Multicenter, Randomized, Double Blind, Placebo Controlled, Phase II Trial Evaluating the Safety and Efficacy of TKI258 Combined with Fulvestrant in Postmenopausal Patients with HER2- and HR+ Breast Cancer that have Evidence of Disease Progression on or after Prior Endocrine Therapy

 
Results per page: 25 50 100 All 1-2 Trials Jump to page:

 
 
  
NCI CCC LogoCity of Hope, An NCI-designated Comprehensive Cancer Center, is an innovative biomedical research, treatment and educational institution dedicated to the prevention and cure of cancer and other life-threatening illness.
Best Of logoCity of Hope has been named one of "America's Best Hospitals" in cancer and gynecology by U.S. News & World Report. Read more here...
NCI CCC LogoThe National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of 21 of the world’s leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer.
Best Of logoWe subscribe to the HONcode of the Healthcare on the Net Foundation.